

# Bernard Bonnotte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1066857/publications.pdf>

Version: 2024-02-01

87  
papers

5,507  
citations

109264

35  
h-index

82499

72  
g-index

95  
all docs

95  
docs citations

95  
times ranked

7214  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. <i>European Journal of Immunology</i> , 2004, 34, 336-344.	1.6	846
2	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2014, 371, 1771-1780.	13.9	842
3	Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer. <i>Cancer Research</i> , 2014, 74, 104-118.	0.4	319
4	Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2499-2503.	6.7	302
5	Pathogenesis of immune thrombocytopenia. <i>Autoimmunity Reviews</i> , 2017, 16, 620-632.	2.5	249
6	Late-Onset Combined Immune Deficiency: A Subset of Common Variable Immunodeficiency with Severe T Cell Defect. <i>Clinical Infectious Diseases</i> , 2009, 49, 1329-1338.	2.9	192
7	Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3788-3798.	6.7	181
8	Recent advances in our understanding of giant cell arteritis pathogenesis. <i>Autoimmunity Reviews</i> , 2017, 16, 833-844.	2.5	150
9	Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. <i>British Journal of Haematology</i> , 2011, 155, 498-508.	1.2	125
10	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2020, 173, 179-187.	2.0	116
11	Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. <i>Blood</i> , 2011, 118, 4394-4400.	0.6	98
12	Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. <i>Autoimmunity Reviews</i> , 2018, 17, 391-398.	2.5	97
13	Stroke associated with giant cell arteritis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 216-221.	0.9	95
14	Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 cases. <i>American Journal of Hematology</i> , 2009, 84, 153-157.	2.0	90
15	Myeloid-derived suppressor cells from tumor-bearing mice impair TGF- $\beta$ -induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25 <sup>hi</sup> FoxP3 <sup>lo</sup> T cells. <i>Journal of Leukocyte Biology</i> , 2012, 92, 987-997.	1.5	84
16	Good Syndrome: An Adult-Onset Immunodeficiency Remarkable for Its High Incidence of Invasive Infections and Autoimmune Complications. <i>Clinical Infectious Diseases</i> , 2015, 61, e13-e19.	2.9	81
17	Giant Cell Arteritis-related Stroke: A Retrospective Multicenter Case-control Study. <i>Journal of Rheumatology</i> , 2017, 44, 297-303.	1.0	76
18	The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-14.	3.3	75

#	ARTICLE	IF	CITATIONS
19	A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. <i>Nature Medicine</i> , 2003, 9, 1215-1219.	15.2	69
20	Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. <i>Blood</i> , 2014, 124, 2858-2866.	0.6	64
21	A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. <i>Blood</i> , 2012, 120, 4938-4944.	0.6	62
22	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013, 42, 1317-1330.	0.8	62
23	Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 1876-1884.	0.4	58
24	Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. <i>Rheumatology</i> , 2015, 54, 940-949.	0.9	58
25	Involvement and prognosis value of CD8 + T cells in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016, 72, 73-83.	3.0	56
26	Venous thromboembolic events during warm autoimmune hemolytic anemia. <i>PLoS ONE</i> , 2018, 13, e0207218.	1.1	49
27	Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments. <i>HemaSphere</i> , 2021, 5, e574.	1.2	45
28	Killer dendritic cells and their potential for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1-11.	2.0	44
29	LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2012, 51, 1906-1915.	0.9	43
30	Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. <i>Blood</i> , 2013, 122, 2477-2486.	0.6	42
31	Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. <i>Haematologica</i> , 2011, 96, 1276-1283.	1.7	41
32	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. <i>Journal of Autoimmunity</i> , 2015, 62, 22-30.	3.0	40
33	Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. <i>Joint Bone Spine</i> , 2011, 78, 241-245.	0.8	39
34	Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loading. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1513-1524.	2.2	36
35	Severe Aplastic Anemia Associated With Eosinophilic Fasciitis. <i>Medicine (United States)</i> , 2013, 92, 69-81.	0.4	36
36	The inhibition of TNF- $\alpha$ anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. <i>Experimental Cell Research</i> , 2007, 313, 2345-2355.	1.2	35

#	ARTICLE	IF	CITATIONS
37	Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice. <i>Journal of Lipid Research</i> , 2013, 54, 3453-3463.	2.0	35
38	Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN- $\gamma$ -Dependent Mechanism. <i>Journal of Immunology</i> , 2011, 187, 6310-6317.	0.4	33
39	B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. <i>Journal of Autoimmunity</i> , 2017, 77, 89-95.	3.0	33
40	Emerging Therapies in Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2021, 10, 1004.	1.0	33
41	Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. <i>American Journal of Hematology</i> , 2013, 88, 858-861.	2.0	31
42	Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018, 50, 12-19.	1.0	30
43	Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3 <sup>+</sup> CD8 <sup>+</sup> T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1614-1624.e4.	1.5	29
44	Cytotoxic Dendritic Cells Generated from Cancer Patients. <i>Journal of Immunology</i> , 2011, 187, 2775-2782.	0.4	23
45	Endovascular stent placement for chronic post-thrombotic symptomatic ilio-femoral venous obstructive lesions: a single-center study of safety, efficacy and quality-of-life improvement. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016, 6, 342-352.	1.1	23
46	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 339-346.	1.6	22
47	Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. , 2000, 86, 827-834.		21
48	Liver X Receptor-Mediated Induction of Cholesteryl Ester Transfer Protein Expression Is Selectively Impaired in Inflammatory Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1923-1929.	1.1	21
49	Freshly isolated bone marrow cells induce death of various carcinoma cell lines. <i>International Journal of Cancer</i> , 2003, 107, 747-756.	2.3	19
50	Allogeneic effector/memory Th-1 cells impair FoxP3 <sup>+</sup> regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. <i>Blood</i> , 2011, 117, 1555-1564.	0.6	19
51	Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2021, 10, e1332.	1.7	18
52	Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. <i>European Journal of Internal Medicine</i> , 2014, 25, 837-842.	1.0	16
53	Dendritic cell-tumor cell hybrids and immunotherapy: what's next?. <i>Cytotherapy</i> , 2011, 13, 774-785.	0.3	15
54	An atypical caspase-independent death pathway for an immunogenic cancer cell line. <i>Oncogene</i> , 2002, 21, 6091-6100.	2.6	13

#	ARTICLE	IF	CITATIONS
55	Is TNF- $\alpha$ really involved in giant cell arteritis pathogenesis?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e1-e1.	0.5	11
56	A New Prognosis Score to Predict Mortality After Acute Pneumonia in Very Elderly Patients. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 1123-1128.	1.2	11
57	Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2020, 9, 1998.	1.0	10
58	New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation. <i>Journal of Clinical Medicine</i> , 2022, 11, 2905.	1.0	10
59	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. <i>RMD Open</i> , 2022, 8, e002160.	1.8	9
60	Alpha-Interferon Secreting Blastic Plasmacytoid Dendritic Cells Neoplasm. <i>American Journal of Dermatopathology</i> , 2012, 34, 626-631.	0.3	8
61	Myocardial infarction during giant cell arteritis: A cohort study. <i>European Journal of Internal Medicine</i> , 2021, 89, 30-38.	1.0	8
62	Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2022, 61, 2464-2471.	0.9	8
63	Splenic and Circulating Human T Follicular Helper Cell Regulation By B Cell Depleting Therapy during Immune Thrombocytopenia. <i>Blood</i> , 2015, 126, 8-8.	0.6	8
64	<sc>PIAS</sc>1 and <sc>STAT</sc> $\beta$ impair the tumoricidal potential of <sc>IFN</sc> $\alpha$ -stimulated mouse dendritic cells generated with <sc>IL</sc>15. <i>European Journal of Immunology</i> , 2014, 44, 2489-2499.	1.6	7
65	Temporal Artery Vascular Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 275.	1.0	7
66	Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. <i>Oncolmunology</i> , 2012, 1, 566-568.	2.1	6
67	Impact of the COVID-19 lockdown on the management and control of patients with GCA. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e102-e102.	0.5	6
68	Mimickers of Large Vessel Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 495.	1.0	6
69	Ustekinumab For the Treatment of Giant Cell Arteritis: Comment on the Article by Matza et al. <i>Arthritis Care and Research</i> , 2021, 73, 1058-1059.	1.5	5
70	COVID-19 Lockdown in Patients with Chronic Diseases: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3957.	1.2	5
71	FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection. , 1999, 82, 359-367.		4
72	T Lymphocyte Plasticity in Autoimmunity and Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-2.	0.9	4

#	ARTICLE	IF	CITATIONS
73	How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network. <i>Blood</i> , 2015, 126, 456-456.	0.6	4
74	Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigoleet al. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e3-e3.	0.5	3
75	Characteristics of Adult Patients with Idiopathic Retroperitoneal Fibrosis and Assessment of Risk of Relapse at Diagnosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1380.	1.0	3
76	T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients. <i>European Journal of Internal Medicine</i> , 2022, 99, 104-105.	1.0	3
77	Efficacy of colchicine alone or in combination with vinca alkaloids in severe corticoid-resistant thrombocytopenic purpura: six cases. <i>American Journal of Medicine</i> , 1999, 107, 645-646.	0.6	2
78	Intravascular malignant lymphomatosis diagnosed on a muscular biopsy: a case report. <i>European Journal of Internal Medicine</i> , 2004, 15, 190-192.	1.0	2
79	Stratégie diagnostique devant la découverte d'une hypogammaglobulinémie en rhumatologie. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2011, 78, 122-127.	0.0	2
80	Adrenal Insufficiency Revealing a Bilateral Adrenal Hemorrhage-Adrenal Infarction Related to Antiphospholipid Syndrome. <i>American Journal of Medicine</i> , 2022, 135, 194-195.	0.6	2
81	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 289-290.	6.7	1
82	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 1134-1135.	6.7	1
83	Does Tocilizumab Indeed Reduce the Frequency of Th17 Cells? Comment on the Article by Thiolat et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 2639-2640.	2.9	1
84	Cost Effectiveness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia.. <i>Blood</i> , 2012, 120, 2157-2157.	0.6	1
85	Failure of Rituximab in Immune Thrombocytopenia Is Associated with the Activation of Splenic CD8 T Cells. <i>Blood</i> , 2012, 120, 623-623.	0.6	1
86	Mortality and Major Cardiovascular Events among Patients with Multiple Myeloma: Analysis from a Nationwide French Medical Information Database. <i>Cancers</i> , 2022, 14, 3049.	1.7	1
87	Evaluation of the Prognostic Value of CD45RO+ and FOXP3+ Cells of the Micro-Environment In Classical Hodgkin Lymphomas Using Tissue Micro Array. <i>Blood</i> , 2010, 116, 2687-2687.	0.6	0